Protein conjugation platform enabling multi-payload antibody-drug conjugates via a novel cystine-tyrosine bond for next-generation cancer therapeutics.
Catena Biosciences' CysTyr Conjugation Platform enables attachment of multiple payloads of any size and complexity to a single antibody through a novel C-Y Bond between naturally occurring amino acids cystine and tyrosine. It supports flexible drug-to-antibody ratios and precise conjugation site control, overcoming limitations of traditional ADCs restricted to single small-molecule payloads with unstable maleimide bonds. With an initial focus on solid tumors with high unmet medical need, the resulting Multi-Payload Conjugates show preclinical superiority to current standards of care. CysTyr Conjugation Platform is a product of Catena Biosciences.